Find a Trial

Trial Summary


Protocol No.CTO-PRE0405
StatusOPEN TO ACCRUAL
Principal InvestigatorRobertson, Michael
ScopeNational
PhasePhase II
Age GroupAdult
TitlePhase II Study of Bendamustine and Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age
DescriptionEligible untreated patients will receive single arm venetoclax, bendamustine and rituximab as induction therapy. After 6 cycles, maintenance rituximab may be administered per physician discretion. Venetoclax is an oral Bcl-2 family protein inhibitor. It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with mantle cell lymphoma. Venetoclax may make the cancer cells sensitive to chemotherapy. This may help to slow down the growth of cancer or may cause cancer cells to die. The purpose of this study is to see if venetoclax in combination with bendamustine and rituximab chemotherapy is effective in treating people who have mantle cell lymphoma and to examine the side effects, good and bad, associated with this combination.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:
  • Age ≥ 60 years
  • Patients should not have prior chemotherapy, radiotherapy or immunotherapy for lymphoma
For a full list of participation criteria, please visit clinicaltrials.gov.
Applicable Disease SitesLeukemia, other
Participating InstitutionsIndiana University (IU)
    Treatment TypeTreatment
    ContactPhone: (317) 278-5632
    Email: iutrials@iu.edu